Addex Annual General Meeting Scheduled for 11 June 2015
Geneva, Switzerland 27 May 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that its Annual General Meeting will take place on Thursday, 11 June 2015, at 11:00 on the 3rd floor of 17, rue du Cendrier, 1201 Geneva (doors open at 10:30).
1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the Business Year 2014.
2. Consultative vote on the Compensation Report for the Business Year 2014.
3. Appropriation of the Results.
4. Discharge of the members of the Board of Directors and of the Executive Management.
5. Elections of members of the Board of Directors and Re-election of the Chairman of the Board of Directors
5.1. Re-election of Vincent Lawton as member of the Board of Directors;
5.2. Election of Raymond Hill as member of the Board of Director;
5.3. Election of Timothy Dyer as member of the Board of Director; and
5.4. Re-election of Vincent Lawton as Chairman of the Board of Directors.
6. Elections of Vincent Lawton and Raymond Hill as the members of the Compensation Committee
7. Re-election of PricewaterhouseCoopers SA, Geneva as Auditors.
8. Re-election of Robert P. Briner, attorney-at-law, Briner & Brunisholz, Cours des Bastions 5, CH-1205 Geneva as the Independent Voting Rights Representative.
9. Amendments to the Articles of Association
9.1. Extension and Increase of the Authorized Share Capital (Article 3b of the Articles of Association);
9.2. Increase of the Conditional Share Capital (Article 3c of the Articles of Association); and
9.3. Amendments to the Articles of Association as a consequence of the Ordinance against Excessive Compensation at Public Corporations (OaEC).
10. Approval of the Compensation of the members of the Board of Directors and of the Executive Management
10.1. Approval of Compensation of the members of the Board of Directors; and
10.2. Approval of Compensation of the members of the Executive Management.
The detailed Annual General Meeting invitation can be found on the Addex Therapeutics website at invitation.
About Addex Therapeutics
Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) has successfully completed a Phase 2A POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase 2B for PD-LID. In parallel, dipraglurant’s therapeutic use in dystonia and treatment resistant depression is being investigated. Addex second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. Addex also has several preclinical programs including: ADX71441 (GABAB receptor PAM) which has received regulatory approval to start Phase 1 and is being investigated for therapeutic use in Charcot-Marie-Tooth (Type 1A) disease, alcohol use disorder and nicotine dependence; mGlu4PAM for drug abuse and dependence, Parkinson’s disease and other neurodegenerative diseases; mGlu2NAM for treatment resistant depression and cognitive deficits; mGlu7NAM for psychosomatic disorders, TrkBPAM for neurodegenerative disorders; and GLP1PAM for type 2 diabetes. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.
Chief Executive Officer
Telephone: +41 22 884 15 61
Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.